Gilead to buy cancer therapy developer Arcellx for up to $7.8 billion CNBCHealth Care Roundup: Market Talk The Wall Street JournalGilead shows belief in its partner's cancer treatment with $7.8 billion buyout MarketWatchUS Premarket Movers: Arcellx, Domino's, MoonLake, Vanda, Veris Bloomberg.com
|